Back to Search
Start Over
Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
- Source :
-
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2003 Mar; Vol. 9 (3), pp. 1200-10. - Publication Year :
- 2003
-
Abstract
- Purpose: We determined whether blockade of the epidermal growth factor receptor (EGF-R) signaling pathway by oral administration of the EGF-R tyrosine kinase inhibitor (PKI 166) alone or in combination with injectable Taxol inhibits the growth of PC-3MM2 human prostate cancer cells in the bone of nude mice.<br />Experimental Design: Male nude mice implanted with PC-3MM2 cells in the tibia were treated with oral administrations of PKI 166 or PKI 166 plus injectable Taxol beginning 3 days after implantation. The incidence and size of bone tumors and destruction of bone were determined by digitalized radiography. Expression of epidermal growth factor (EGF), EGF-R, and activated EGF-R in tumor cells and tumor-associated endothelial cells was determined by immunohistochemistry.<br />Results: Oral administration of PKI 166 or PKI 166 plus injectable Taxol reduced the incidence and size of bone tumors and destruction of bone. Immunohistochemical analysis revealed that PC-3MM2 cells growing adjacent to the bone expressed high levels of EGF and activated EGF-R, whereas tumor cells in the adjacent musculature did not. Moreover, endothelial cells within the bone tumor lesions, but not in uninvolved bone or tumors in the muscle, expressed high levels of activated EGF-R. Treatment with PKI 166 and more so with PKI 166 plus Taxol significantly inhibited phosphorylation of EGF-R on tumor and endothelial cells and induced significant apoptosis and endothelial cells within tumor lesions.<br />Conclusions: These data indicate that endothelial cells exposed to EGF produced by tumor cells express activated EGF-R and that targeting EGF-R can produce significant therapeutic effects against prostate cancer bone metastasis.
- Subjects :
- Administration, Oral
Animals
Antineoplastic Agents, Phytogenic pharmacology
Blotting, Western
Bone Neoplasms pathology
Bone and Bones metabolism
Dose-Response Relationship, Drug
Endothelial Growth Factors biosynthesis
Endothelium, Vascular metabolism
Endothelium, Vascular pathology
ErbB Receptors antagonists & inhibitors
ErbB Receptors biosynthesis
Fibroblast Growth Factor 2 metabolism
Immunohistochemistry
In Situ Nick-End Labeling
Intercellular Signaling Peptides and Proteins biosynthesis
Interleukin-8 biosynthesis
Lymphokines biosynthesis
Male
Mice
Mice, Nude
Microscopy, Fluorescence
Neoplasm Metastasis
Neoplasm Transplantation
Paclitaxel pharmacology
Phosphorylation
Platelet Endothelial Cell Adhesion Molecule-1 biosynthesis
Proliferating Cell Nuclear Antigen biosynthesis
Prostatic Neoplasms drug therapy
Prostatic Neoplasms pathology
Pyrimidines pharmacology
Pyrroles pharmacology
Tumor Cells, Cultured
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
ErbB Receptors metabolism
Signal Transduction
Subjects
Details
- Language :
- English
- ISSN :
- 1078-0432
- Volume :
- 9
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publication Type :
- Academic Journal
- Accession number :
- 12631626